Squarepoint
CAPR icon

Squarepoint’s Capricor Therapeutics CAPR Stock Holding History

Squarepoint’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,600
Closed -$146K – 4646
2024
Q4 		$146K Buy
+10,600
New +$186K ﹤0.01% 4579

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Squarepoint's CAPR Position: Q2 2026 in Review

Squarepoint increased its Capricor Therapeutics (CAPR) stake by 58% in Q2 2026, buying an estimated $219K and bringing the position to 19,731 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #3464.

Squarepoint first reported a position in CAPR in Q2 2024 and has held it in 6 quarters since. The position peaked at $1.62M in Q1 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Squarepoint held 19,731 shares of Capricor Therapeutics worth $475K as of Q2 2026.
  • Squarepoint bought 7,231 Capricor Therapeutics shares in Q2 2026, an estimated $219K.
  • Capricor Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3464 holding.
  • Squarepoint first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Squarepoint's Capricor Therapeutics position peaked at $1.62M in Q1 2025.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.